Skip to main content
. 2019 Aug 3;33(4):670–677. doi: 10.5713/ajas.19.0463

Table 2.

Pharmacokinetic parameters of LMT-28 after intravenous and oral administration at doses of 5 mg/kg in male BALB/c mice (n = 4)

Parameters Intravenous (i.v) Oral (p.o.)
Dose (mg/kg) 5 5
Tmax (h) - 0.80±0.67
Cmax (ng/mL) - 137±100
t1/2 (h) 1.37±0.29 1.13±0.27
CL (L/h/kg) 8.66±4.51 -
Vss (L/kg) 12.9±4.66 -
AUC8h (h·ng/mL) 661±253 292±202
AUC (h·ng/mL) 677±264 302±209
MRT (h) 1.58±0.32 1.9±0.55
F (%) - 38.2

Data represent mean±standard deviation.

Tmax, the time to reach a peak concentration; Cmax, peak plasma concentration; t1/2, terminal elimination half-life; CL, clearance; Vss, distribution volume at steady state; AUC8h, area under the plasma concentration-time curve values of LMT-28 during 8 h; AUC, able to cover approximately 96.7% of the total AUC; MRT, mean residence time; F, bioavailability.